FDA warns Shionogi over postmarketing studies; billionaire Singh brothers prepared to fight Daiichi;

 @FiercePharma: Novo Nordisk figures it could launch Victoza (liraglutide) as obesity treatment by end of 2014. Story | Follow @FiercePharma

 @EricPFierce: Yes, J&J has an impressive pipeline, but its extensions of existing drugs could add billions to the top line. Report | Follow @EricPFierce

> The FDA has sent a notice to Japanese drugmaker Shionogi for the failing to do required postmarketing studies on its pain drug Rybix ODT. Story

> The FDA said it has approved COBAS INTEGRA 800 Tina-quant HbA1cDx assay as the first HbA1c test for the diagnosis of diabetes. Announcement

>  The World Health Organization (WHO) has warned countries with possible cases of the SARS-like novel coronavirus that the need to share information on the lethal virus. Story

> Under pressure from activist hedge fund manager Bill Ackman, Procter & Gamble has replaced Chairman and CEO Bob McDonald with its former CEO A.G. Lafley. Story

Medical Device News

 @FierceMedDev: Roche wins FDA approval for novel diabetes diagnostic. More | Follow @FierceMedDev

 @MarkHFierce: Looks like Panasonic's bid to attract new investment for its healthcare arm is drawing major interest. Story | Follow @MarkHFierce

 @DamianFierce: Intuitive won its first da Vinci lawsuit, dodging $8.5M in damages. Article | Follow @DamianFierce

> Ethicon study asserts safety of medical-grade polycarbonate devices. Story

> Covidien, Kona Medical trumpet new tech at EuroPCR. More

> Covidien's board approves pharma spinoff. Article

Biotech News

 @FierceBiotech: Check out this week's roundup of job changes in biopharma via @MichaelGFierce and @EmilyMFierce. Report | Follow @FierceBiotech

 @JohnCFierce: Aveo shares shellacked after Astellas drops EU game plan on kidney cancer. More | Follow @JohnCFierce

 @RyanMFierce: Merck marks another failure in elusive hunt for Parkinson's disease drugs. Article | Follow @RyanMFierce

> Amid deal frenzy, Elan rejects latest buyout bid from Royalty Pharma. Article

> Pfizer denies knowledge of acquired companies' failures in East German drug trials. Story

> Merck Serono CEO stakes out Boston biotech startups. More

And Finally... The billionaire Singh brothers have the will and the way to fight Japanese drugmaker Daiichi Sankyo, who this week said it might sue them for allegedly covering up the problems at Ranbaxy Laboratories when they sold controlling interest to the company in 2008. Story

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.